Company
LON:POLB
Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity. Poolbeg is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world’s largest markets. With multiple near-term clinical value inflection points, and an experienced team with a proven track record, Poolbeg is focussed on partnering its high value programmes that are targeting large markets and addressing critical unmet medical needs.
135 stories · page 7 of 7
Archive
Tertiary Minerals 0.2p £3.15m (LON:TYM) The mineral exploration and development company, whose strategic focus is on energy transition and precious metals announced that contractors have been appointed for the Company's upcoming drill progr
It has partnered with OneThree Biotech, a pioneer of artificial intelligence in the drugs arena
The deal looks to be a prelude to creating and offering oral vaccines
It is noteworthy that Poolbeg has been able to obtain rights to these products against the background of anti-infectives coming back into focus
The company will add to its pipeline a potential immunotherapy for respiratory virus infections
While anti-vaxxers continue to rail against mass inoculation, a major impediment to compliance continues to be the use of needles to administer the protection against the virus
Also known as Whitmore's disease, melioidosis is found in the soil and surface groundwater of many tropical and subtropical regions, causing pneumonia and severe sepsis with multiple organ abscesses
Professor Daniel Hoft has 32 years of experience and has published over 140 peer-reviewed articles
The company has set Germany drug business Evotec as the benchmark
POLB 001 is what’s called an immunomodulator, which means it helps fight infection. It is being developed to treat severe flu
PredictViral is being developed to be used to detect respiratory viruses such as influenza, respiratory syncytial virus and human rhinoviruses that cause over half of all common colds
The collaboration with Eurofins is a ‘key step’ to commencing artificial intelligence analysis of its data and will mean it then has full immunological datasets for respiratory syncytial virus
Chief executive Jeremy Skillington said: "Our US patent assessment is going to plan and we look forward to updating our shareholders when we receive confirmation of its grant."
Archive
A look at some of the major movers in London on Monday
He said the company’s capital-light model has been well received by investors, said chief executive Jeremy Skillington
